RT Journal Article
T1 A new potential nano-oncological therapy based on polyamino acid nanocapsules
A1 Gonzalo, Teresa
A1 Lollo, Giovanna
A1 García-Fuentes, Marcos
A1 Torres, Dolores
A1 Correa, Juan
A1 Riguera Vega, Ricardo
A1 Fernández Megía, Eduardo
A1 Calvo, Pilar
A1 Avilés, Pablo
A1 Guillén, Maria José
A1 Alonso Fernández, María José
K1 Nanomedicines
K1 Long-circulating nanocarriers
K1 Nanocapsules
K1 Polyglutamic acid
K1 Cancer
AB A critical objective in cancer therapy is to reduce the systemic toxicity through the modification of the biodistribution of anticancer drugs. Herein, we disclose a new biodegradable nanocarrier, polyglutamic acid (PGA) nanocapsules, and present the in vivo pharmacokinetics/toxicity proof-of-concept for the anticancer drug plitidepsin. These novel nanocapsules were prepared using a modified solvent displacement technique where the polyamino acid was electrostatically deposited onto the lipid core. The nanocapsules exhibited an average size of 200 nm, a negative zeta potential and a great capacity for the encapsulation of plitidepsin (encapsulation efficiency above 90%). In addition, the nanocapsules could be freeze-dried and showed an adequate stability profile upon storage. Finally, the in vivo proof-of-concept studies performed in mice indicated that the encapsulation provided the drug with a prolonged blood circulation and a significantly reduced toxicity. In fact, the maximum tolerated dose of the nanoencapsulated drug was more than 3 times that of the reference formulation (Cremophor® EL plitidepsin solution). Overall, beyond the value of this specific formulation, the work reported here represents the evidence of the potential of polyamino acid nanocapsules in nano-oncological therapy
PB Elsevier
SN 0168-3659
YR 2013
FD 2013-07
LK http://hdl.handle.net/10347/16975
UL http://hdl.handle.net/10347/16975
LA eng
NO Gonzalo, T., Lollo, G., Garcia-Fuentes, M., Torres, D., Correa, J., & Riguera, R. et al. (2013). A new potential nano-oncological therapy based on polyamino acid nanocapsules. Journal Of Controlled Release, 169(1-2), 10-16. doi: 10.1016/j.jconrel.2013.03.037
NO The authors would like to acknowledge financial support from CENIT-NANOFAR XS53 project, PharmaMar, Spain, the Ministry of Sciences and Innovation ((CTQ2009-10963), the Xunta de Galicia (Competitive Reference Groups-FEDER funds Ref. 2010/18, and CN2011/037) and the European Commission FP7 EraNet — EuroNanoMed Program-Instituto Carlos III (Lymphotarg proyect, Ref. PS09/02670). Giovanna Lollo has a fellowship from the Ministry of Education of Spain. Marcos Garcia Fuentes acknowledges an Isidro Parga Pondal Fellowship from Xunta de Galicia
DS Minerva
RD 24 abr 2026